GOLDMAN SACHS GROUP INC - ADAPTIVE BIOTECHNOLOGIES COR ownership

ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2021. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ADAPTIVE BIOTECHNOLOGIES COR
ValueSharesWeighting
Q3 2023$9,249,599
-35.9%
1,697,174
-21.0%
0.00%
-33.3%
Q2 2023$14,421,333
+8.9%
2,149,230
+43.3%
0.00%0.0%
Q1 2023$13,242,678
+34.3%
1,499,737
+16.2%
0.00%
+50.0%
Q4 2022$9,859,993
-27.4%
1,290,575
-32.3%
0.00%
-33.3%
Q3 2022$13,575,000
+25.2%
1,906,589
+42.2%
0.00%
+50.0%
Q2 2022$10,845,000
-33.6%
1,340,482
+14.0%
0.00%
-33.3%
Q1 2022$16,325,000
-55.9%
1,176,102
-10.9%
0.00%
-57.1%
Q4 2021$37,021,000
-14.3%
1,319,373
+3.8%
0.01%
-22.2%
Q3 2021$43,215,000
-23.3%
1,271,398
-7.8%
0.01%
-30.8%
Q2 2021$56,337,000
+23.7%
1,378,765
+21.8%
0.01%
+18.2%
Q1 2021$45,558,000
-10.3%
1,131,599
+31.7%
0.01%
-15.4%
Q4 2020$50,815,000
-16.5%
859,382
-31.3%
0.01%
-23.5%
Q3 2020$60,856,000
+11.3%
1,251,425
+10.7%
0.02%0.0%
Q2 2020$54,679,000
+223.9%
1,130,193
+86.0%
0.02%
+183.3%
Q1 2020$16,879,000
+25.4%
607,588
+35.1%
0.01%
+100.0%
Q4 2019$13,460,000
+75.8%
449,893
+81.6%
0.00%
+50.0%
Q3 2019$7,655,000
+4.2%
247,710
+62.8%
0.00%0.0%
Q2 2019$7,348,000152,1290.00%
Other shareholders
ADAPTIVE BIOTECHNOLOGIES COR shareholders Q4 2021
NameSharesValueWeighting ↓
Blue Water Life Science Advisors, LP 2,377,665$12,958,27412.23%
Eagle Health Investments LP 1,214,860$6,620,9871.46%
Matrix Capital Management Company, LP 11,572,590$63,070,6160.76%
Aristotle Atlantic Partners, LLC 3,058,206$16,667,2230.67%
VIKING GLOBAL INVESTORS LP 29,993,708$163,465,7090.66%
Pier Capital, LLC 719,067$3,918,9150.63%
DDD Partners, LLC 783,697$3,385,5710.49%
ARK Investment Management 11,509,308$62,725,7280.48%
Nikko Asset Management Americas, Inc. 6,570,939$35,680,1990.43%
Triatomic Management LP 102,889$560,7450.39%
View complete list of ADAPTIVE BIOTECHNOLOGIES COR shareholders